Treatment
Empagliflozin clinical trials
We’re tracking 82 recruiting studies that include Empagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT06894784RecruitingPhase 3
Combining two diabetes drugs with an automated insulin pump
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
Montreal, QuebecAges 18 years+ - NCT07845630RecruitingPhase 1
Comparing two tablet forms of a study drug in healthy people
This study compares how two different tablet versions of a combination of vicadrostat and empagliflozin are absorbed by the body. It is for healthy volunteers to see which form works better.
BiberachAges 18–55 - NCT07452913Enrolling by invitationPhase 4
Comparing Diabetes Drug Combinations in Newly Treated Adults
This trial compares two different combinations of diabetes pills (metformin plus empagliflozin with either sitagliptin or linagliptin) in people with type 2 diabetes who have not been treated before. It aims to see which combination works better and is safer for controlling blood sugar.
Karachi, SindhAges 30–55 - NCT07322237RecruitingPhase 4
Study on heart function drugs for liver cirrhosis patients
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
ChandigarhAges 18–65 - NCT07074418RecruitingPhase 4
Empagliflozin for advanced kidney disease in type 2 diabetes
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
Nice, Alpes-MaritimesAges 18–80 - NCT06989723RecruitingPhase 4
Pioglitazone and empagliflozin for fatty liver in type 2 diabetes
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
Seongnam-siAges 20 years+ - NCT07053319RecruitingPhase 1
Study of diabetes drugs and ketones
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
San Antonio, TexasAges 30–75 - NCT06030843RecruitingPhase 2/Phase 3
Testing empagliflozin for heart and kidney health
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
Bangkok, PathumwanAges 18 years+ - NCT05138575RecruitingPhase 2
Testing SGLT2 pill and potassium nitrate for heart failure with preserved EF
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07771010RecruitingPhase 4
Comparing empagliflozin and metformin for muscle health in type 2 diabetes
This study tests two diabetes medications, empagliflozin and metformin, to see how they affect muscle energy use and blood flow in men with recently diagnosed type 2 diabetes. Participants will be followed at a diabetes clinic.
LjubljanaAges 18–75 - NCT07700940RecruitingPhase 4
Empagliflozin for kidney function in lupus nephritis
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Banī SuwayfAges 18–65 - NCT07692256RecruitingPhase 2
Empagliflozin for heart failure in children
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
Cairo, Cairo GovernorateAges 1 month–18 years - NCT06715449RecruitingPhase 2/Phase 3
Testing empagliflozin after a stroke with unknown cause
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
Cambridge, CambridgeshireAges 18 years+ - NCT06095492Recruiting
Comparing diabetes drugs after kidney transplant
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
Gurgaon, HaryanaAges 30 years+ - NCT06249932RecruitingPhase 4
Empagliflozin for heart failure and end-stage kidney disease
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
Hsinchu, TaiwanAges 20 years+ - NCT06249945RecruitingPhase 4
Empagliflozin for heart failure with preserved ejection fraction and dialysis
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
HsinchuAges 20 years+ - NCT07336797RecruitingPhase 2
Empagliflozin for weight and metabolism in HIV
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
CairoAges 18–65 - NCT07331389RecruitingPhase 1
How HDM1002 interacts with common drugs and diabetes medications
This study tests how a new drug called HDM1002 interacts with common diabetes medications (metformin, empagliflozin) and other drugs like warfarin and valsartan. If you are a generally healthy adult (age 18-45) with a higher BMI, this trial helps ensure the new drug is safe when taken with other medicines.
HefeiAges 18–45 - NCT07292909RecruitingPhase 4
Effect of Empagliflozin on Inflammation for Coronary Patients
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
Beirut, BeirutAges 18 years+ - NCT06706791RecruitingPhase 4
Empagliflozin for heart failure & diabetes: quality of life study
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Karachi, SindhAges 40–70 - NCT07228195RecruitingPhase 4
Study on SGLT2i therapy after islet transplantation
This trial tests whether a diabetes medication called empagliflozin (an SGLT2 inhibitor) can help people who have had an islet transplant (TPIAT) better manage their blood sugar. It aims to see if it improves how well the transplanted islets work.
Minneapolis, MinnesotaAges 18–70 - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07093476RecruitingPhase 3
Adding empagliflozin to improve blood sugar control
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
SeoulAges 19 years+ - NCT07064473RecruitingPhase 3
Testing vicadrostat plus empagliflozin for diabetes, high blood pressure, and heart disease
This study tests a new pill called vicadrostat taken with another medicine (empagliflozin) to see if it helps people with type 2 diabetes, high blood pressure, and heart disease. It may reduce the risk of heart problems, but you must not have had heart failure or use certain other heart medications.
Anniston, AlabamaAges 18 years+
What Empagliflozin is being studied for
Conditions with recruiting Empagliflozin studies.
Common questions
- Are there clinical trials studying Empagliflozin?
- Yes. Clin2 currently lists 82 recruiting studies that include Empagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Empagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Empagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Empagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.